Table 1.

Clinical and laboratory characteristics of MDS patients

	No.	% BM blasts	2016 WHO classification	Karyotype	IPSS risk	IEX-1 mRNA	% CD71+ reticulocytes	% Mito− reticulocytes
Other MDS	1	<5	MDS-MLD	Del(11q23), + 8	Int-1	0.7	0.29	13.7
	2	<5	MDS-MLD	Add(1)(p23)	Int-1	1.5	4.42	4.5
	3	<5	MDS-MLD	Normal	Int-1	0.8	2.33	34.3
	4	15	t-MDS	−7	High	0.6	0.33	22.8
	6	<5	t-MDS	Normal	Int-1	0.7	2.27	24.3
	9	6	CMML-1 (low WBC dysplastic subtype)	Normal	Int-1	3.0	1.13	33
	10	6	MDS-EB1 (rings 30%)	Complex	Int-2	2.6	1.52	39.2
	11	<5	MDS/MPN-RS-T	Normal	Low	4.5	0.40	24.4
	12	<5	MDS-MLD	Normal	Int-1	1.4	2.13	34
	13	7	MDS-EB1	Complex	Int-2	1.0	0.72	2.7
	14	<5	MDS-SLD-RS	Normal	Low	2.5	0.68	32.4
	15	8	MDS-EB1	Complex	Int-2	0.7	0.96	37.4
	16	9	MDS-EB1	Normal	Int-1	1.8	3.04	29.6
	18	<5	MDS-MLD	Del(20) (q12q13)	Int-1	0.9	0.50	43.8
	19	<5	t-MDS	Der(1;7), + 1	Int-1	0.6	0.30	44.7
	20	<5	MDS-MLD-RS	Normal	Low	1.0	4.49	1.7
	21	<5	MDS-SLD-RS	Normal	Low	0.8	0.10	4.7
	22	8	t-MDS	+13	Int-2	0.8	0.01	17.1
Low IEX-1	5	18	MDS-EB2	Del(5)(q13q33)	Int-2	0.3	1.41	69.0
	7	14	MDS-EB2	Del(9)(q)	High	0.2	1.84	70.8
	8	<5	t-MDS	Der(1;7), +1	Int-1	0.3	1.02	73.4
	17	9	MDS-EB1	Normal	Int-1	0.3	1.03	67.9
	23	<5	MDS-MLD	Del(20) (q12q13)	Low	0.3	1.68	62.8
Average value of healthy donors (mean ± SD):						1.0 ± 0.4	0.06 ± 0.04	5.4 ± 3.2